Advertisement

Can This New Drug Boost Pfizer's Stock?

Can This New Drug Boost Pfizer's Stock?

Pfizer's (NYSE: PFE) nasal spray Zavzpret was given the green light by the Food and Drug Administration earlier this month to treat patients with acute migraine. With this approval, the pharmaceutical company now has an acute migraine treatment in nasal spray form to complement the oral treatment in its portfolio, Nurtec ODT. What could Zavzpret contribute to Pfizer's top line?